Provided by Tiger Fintech (Singapore) Pte. Ltd.

Karyopharm Therapeutics

5.72
-0.1100-1.89%
Volume:24.07K
Turnover:137.78K
Market Cap:48.14M
PE:-0.41
High:5.83
Open:5.72
Low:5.64
Close:5.83
Loading ...

Karyopharm Therapeutics (KPTI) Receives a Buy from Piper Sandler

TIPRANKS
·
4 hours ago

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PR Newswire
·
04 Mar

Karyopharm Therapeutics Is Maintained at Outperform by Baird

Dow Jones
·
03 Mar

Karyopharm Therapeutics Inc : Baird Cuts Target Price to $54 From $75

THOMSON REUTERS
·
28 Feb

Karyopharm Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
26 Feb

Karyopharm Therapeutics Inc : H.c. Wainwright Adjusts Target Price to $56 From $7 to Reflect 1-for-15 Reverse Stock Split

THOMSON REUTERS
·
26 Feb

Karyopharm trading halted, news pending

TIPRANKS
·
26 Feb

Karyopharm Therapeutics to Implement 1-for-15 Reverse Stock Split

MT Newswires Live
·
25 Feb

Karyopharm Announces 1-for-15 Reverse Stock Split

THOMSON REUTERS
·
24 Feb

Karyopharm Announces 1-for-15 Reverse Stock Split

PR Newswire
·
24 Feb

Karyopharm Therapeutics: Hold Rating Maintained Amid Revenue Stagnation and Competitive Pressures

TIPRANKS
·
23 Feb

Karyopharm Therapeutics Price Target Maintained With a $7.00/Share by HC Wainwright & Co.

Dow Jones
·
20 Feb

Karyopharm Therapeutics: Strong Financial Performance and Strategic Developments Justify Buy Rating

TIPRANKS
·
20 Feb

Karyopharm Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St.
·
20 Feb

Barclays Sticks to Its Buy Rating for Karyopharm Therapeutics (KPTI)

TIPRANKS
·
20 Feb

Karyopharm Therapeutics Inc (KPTI) Q4 2024 Earnings Call Highlights: Navigating Revenue ...

GuruFocus.com
·
20 Feb